The Serine Protease Inhibitor Protease Nexin-1 Controls Mammary Cancer Metastasis through LRP-1–Mediated MMP-9 Expression

Bérgère Fayard,1 Fabrizio Bianchi,2 Julien Dey,1 Eliza Moreno,1 Sabrina Djaffer,1 Nancy E. Hynes,1 and Denis Monard1

1Friedrich Miescher Institute for Biological Research, Basel, Switzerland and 2FIRC Institute for Molecular Oncology Foundation, Milan, Italy

Abstract
Through their ability to degrade the extracellular matrix, proteases mediate cancer cell invasion and metastasis. Paradoxically, some serine protease inhibitors (serpins) are often overexpressed in human tumors. Using computational analysis, we found that the RNA level of protease nexin-1 (PN-1), a serpin that blocks numerous proteases activity, is significantly elevated in estrogen receptor-α-negative and in high-grade breast cancer. The in silico approach was complemented by mechanistic studies on two mammary cancer cell lines, the PN-1-negative 168FARN cells and the PN-1-positive 4T1 cells, both of which form primary mammary tumors, but only 4T1 tumors are able to metastasize to the lungs. We show that treatment of 168FARN cells with PN-1 stimulates extracellular signal-regulated kinase activation via low-density lipoprotein receptor-related protein-1 (LRP-1) binding, resulting in increased matrix metalloproteinase (MMP)-9 RNA, protein, and secreted activity. PN-1–silenced 4T1 cells express low MMP-9 levels. Moreover, injection of PN-1–silenced cells into mice did not affect 4T1 primary mammary tumor outgrowth; however, the tumors had impaired metastatic potential, which could be restored by reexpressing soluble MMP-9 in the PN-1–silenced 4T1 cells. Thus, using mammary tumor models, we describe a novel pathway whereby the serpin PN-1 by binding LRP-1 stimulates extracellular signal-regulated kinase signaling, MMP-9 expression, and metastatic spread of mammary tumors. Importantly, an analysis of 126 breast cancer patients revealed that those whose breast tumors had elevated PN-1 were more likely to relapse. These results suggest that PN-1 might become a prognostic marker in breast cancer. [Cancer Res 2009;69(14):5690–8]

Introduction
Disease recurrence and metastasis are the primary cause of cancer treatment failure and patient death. Metastasis is a multistep process involving different interrelated events (1). To

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Requests for reprints: Nancy E. Hynes, Growth Control Department, Friedrich Miescher Institute for Biological Research, Maulbeerstrasse 66, 4058 Basel, Switzerland. Phone: 41-61-697-81-07; Fax: 41-61-697-39-76; E-mail: nancy.hynes@fmi.ch.

Cell, Tumor, and Stem Cell Biology

Cancer Res 2009; 69: (14). July 15, 2009 5690 www.aacrjournals.org

Downloaded from cancerres.aacrjournals.org on April 15, 2017. © 2009 American Association for Cancer Research.
mammary tumors when injected in fat pads of BALB/c mice, but only the 4T1 tumors metastasize to the lungs (20). We show that treatment of 168FARN cells with exogenous PN-1 induces MMP-9 RNA and protein expression, which is dependent on LRP-1 binding and extracellular signal-regulated kinase (ERK) activation. Moreover, short hairpin RNA (shRNA)-mediated PN-1 silencing in 4T1 cells causes a decrease in MMP-9 expression. Injection of PN-1–silenced 4T1 cells in mammary glands had no effect on outgrowth of primary mammary tumors; however, these tumors showed a dramatic impairment in their metastatic potential, which we show is due to the decrease in MMP-9 levels. Finally, in a microarray gene expression meta-analysis, we found that PN-1 levels are significantly increased in estrogen receptor (ER)-α-negative and in high-grade breast tumors. Furthermore, an analysis of 126 breast cancer patients revealed that those whose breast tumors had elevated PN-1 levels had a significantly higher probability to develop lung metastasis on relapse compared with metastasis to other sites. These results suggest that PN-1 might become a prognostic marker in breast cancer.

### Materials and Methods

#### Reagents and antibodies.
Mouse anti-PN-1 antibody (clone 4B3) was described previously (21). Rabbit anti-phospho-ERK1/2 (Thr202/Tyr204), anti-ERK1/2, anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-p38 mitogen-activated protein kinase (Thr180/Tyr182), anti-p38 mitogen-activated protein kinase, and anti-phospho-STAT3 (Tyr705) were purchased from Cell Signaling. Anti-STAT3 was purchased from Transduction Labs. Rabbit anti-MMP-9 was from Abcam and monoclonal anti-actin was purchased from Chemicon. PN-1/protease complex inhibitory peptide (P960) and the control scramble peptide (P965), described in ref. 22, were purchased from Chemicon.

#### Western and zymography analyses.
Before collecting cell lysates for Western analysis or conditioned medium for zymography, 168FARN cells were starved in DMEM, and mouse embryonic fibroblasts (MEF) and 4T1 cells were starved in DMEM/1% stripped bovine serum albumin for 12 to 24 h. Immunoblots and zymographies were done as described previously (24).

#### Generation of PN-1-shRNA 4T1 clones and MMP-9 “rescued” clones.
shRNAs were designed according to the Ambion Web site. Two PN-1 mRNA target sequences were designed: PN-1-shRNA1 5′-AGAAACGGA-CATTCTGGGAC-3′ and PN-1-shRNA2 5′-GCCGGGTACCTGTACATG-3′. shRNAs were cloned into pSilencer 1.0-U6 (Ambion) according to the manufacturer’s instructions. 4T1 cells were cotransfected with the pSilencer PN-1-shRNA constructs and a vector encoding puromycin resistance using Lipofectamine 2000 (Invitrogen) as described (25). The empty pSilencer and puromycin vector were cotransfected to generate mock-transfected 4T1 cells. Clones that grew in DMEM/10% FCS with 20 μg/mL puromycin were isolated and examined for PN-1 levels by immunoblotting. To generate MMP-9 (or control) “rescued” 4T1 cells, two PN-1 knockdown (KD) clones (PN-1-shRNA1 clone 1 and PN-1-shRNA2 clone 1) were transfected with pcDNA-MMP-9 or with pcDNA. Two days post-transfection, stable pools were selected in medium containing 2 mg/mL neomycin.

#### Microarray gene expression analysis.
The Oncomine Research Web site was used to perform all the analyses of PN-1 expression across tumor data sets. In the Oncomine database, expression values are first log2 transformed, the median value per microarray is scaled to zero, and SD of values of each microarray is scaled to 1. We used P value cutoff of 0.05 (Student’s t test) to select tumor data sets that displayed differentially expressed PN-1. Normalized log2 expression data of PN-1 were downloaded from the Oncomine Web site for further analyses.

For our analysis on PN-1 and metastasis, we used two publicly available data sets of patients (82 from ref. 26 and 58 from ref. 27). Primary breast tumor Affymetrix gene expression data were downloaded from Gene Expression Omnibus data repository; relative accession numbers are reported in Results. The Affymetrix data were MAS5 normalized as described by the authors (26). We required at least a 5-year follow-up for patients without any metastasis, which resulted in the exclusion of 14 patients. Furthermore, we considered at least a >1.25-fold cutoff for PN-1-overexpressing primary breast tumors. Kaplan-Meier plots were generated by JMP IN software (SAS).

#### In vivo analyses of tumor and metastasis formation.
Animal experiments were done according to the Swiss laws governing animal experimentation and approved by the Swiss veterinary authorities. 4T1 cells (5 × 106) were injected in the fourth mammary fat pad of BALB/c mice (Charles River). For the experiment in Supplementary Fig. S7, parental 4T1 cells were injected into offspring of matings between PN-1 ± BALB/c mice. Once palpable, tumors were measured two to three times per week and size was calculated using the formula: height β [diameter / 2]² × π. On day 26, mice were sacrificed and tumors and lungs were dissected. Lungs were placed in Bouin’s solution to visualize and count metastases.

A description of additional methods is provided in Supplementary Data.

### Results

#### Differential PN-1 expression in mammary tumor cell lines.
To investigate the role of PN-1 in cancer, we used the mammary carcinoma cell lines 168FARN and 4T1, which were isolated from a spontaneous BALB/c mammary tumor (20). Although both cell lines give rise to primary tumors following injection in the mammary fat pad, their invasive and metastatic behaviors differ (28, 29). Indeed, 168FARN cells only disseminate from primary tumors to the lymph nodes (28), whereas the 4T1 cells form tumors that metastasize to multiple sites including lungs (28, 29). PN-1 protein was not detected in 168FARN cells but was high in 4T1 cells (Fig. 1A, top). Thus, these cell lines represent interesting models to study the role of PN-1 in metastasis. PN-1 was shown previously to promote invasion of pancreatic cancer cells (17). Thus, we monitored activity of the secreted gelatinases MMP-9 and MMP-2, two crucial players in invasion, using zymography done on conditioned medium from these cells. 168FARN cells exhibit low MMP-9 and MMP-2 activity, whereas 4T1 cells have comparatively higher MMP-9 and lower MMP-2 activity (Fig. 1A, bottom).

To determine whether a link exists between PN-1 and gelatinase activity, the PN-1-negative 168FARN cells were treated with recombinant PN-1 and secreted gelatinase activity was measured 24 h later. PN-1 (0.2 μmol/L) induced an increase in MMP-9 activity without changing MMP-2 activity (Fig. 1B). Immunoblot analysis on conditioned medium of PN-1-treated 168FARN cells also revealed an increase in secreted MMP-9 (Supplementary Fig. S1). MMP-9 RNA levels were monitored by real-time PCR revealing that PN-1 caused a >40% increase of MMP-9 RNA, evident after 4 h of treatment (Fig. 1C, top). A Western analysis showed that MMP-9 and pro-MMP-9 protein levels increased with similar kinetics (Fig. 1C, bottom). It is worth mentioning that the conditioned medium of 168FARN and 4T1 cells reveals one band of MMP-9
activity, which represents the active form of the gelatinase (data not shown). In summary, PN-1 treatment of 168FARN cells causes an increase in MMP-9 RNA and protein resulting in an increase in secreted active MMP-9.

Effects on MMP-9 expression are enhanced when PN-1 is complexed with a target protease. Serpins are generally complexed with their target proteases; indeed, high levels of serpin/protease complexes are found in many types of human cancer (30, 31). Thus, we examined the effect of PN-1/protease complexes on MMP-9 activity. 168FARN cells were incubated with PN-1 or tPA alone or with PN-1/tPA complexes and zymography was done on conditioned medium. Quantification revealed that tPA had essentially no effect. PN-1 caused a significant 20% increase in activity, whereas the PN-1/tPA complex induced an 85% increase in MMP-9 activity (Fig. 1D, top). Thrombin was also tested and yielded comparable results. The PN-1/thrombin complex was more efficient than PN-1 alone, causing a 50% increase in released MMP-9 activity (Fig. 1D, bottom). Thus, the stimulatory effect of PN-1 on MMP-9 activity is more pronounced when the serpin is complexed with target proteases.

LRP-1 mediates PN-1 effects. LRP-1 is a scavenger receptor responsible for serpin/protease catabolism. LRP-1 binds PN-1 with low affinity, whereas PN-1/protease complexes show high affinity binding (32, 22). In the following experiments, we examined the role of LRP-1 in the PN-1 effects on MMP-9 expression. Wild-type and LRP-1 knockout MEFs were treated with tPA, PN-1, or the PN-1/tPA complex and zymography was done on conditioned medium from the cells. In wild-type MEFs, there was an induction of MMP-9 activity, with the PN-1/tPA complex having the strongest effect (Fig. 2A, top), whereas, in LRP-1 knockout MEFs, none of the treatments stimulated MMP-9 activity (Fig. 2A, bottom). To substantiate the importance of the receptor in 168FARN cells, control and LRP-1-KD cells (Fig. 2B) were treated with the PN-1/tPA complex. MMP-9 activity was 40% lower in conditioned medium from LRP-1-KD cells compared with control cells (Fig. 2C). These results show the importance of LRP-1 in PN-1–mediated MMP-9 induction. In the final experiment, we tested the effect of P960, a 12-aminoacid peptide that was uncovered in a screen for peptides able to block PN-1/protease binding to LRP-1 (22). Treatment of 168FARN cells with 100 to 200 ng/mL P960 abrogated the ability of PN-1 to induce MMP-9 activity, whereas the control scramble peptide P965 had no effect on PN-1 activity (Fig. 2D). In conclusion, these results show that the recombinant PN-1 formed complexes with target proteases secreted...
by the 16FARN cells and it is this physiologically relevant PN-1/protase complex, via binding to LRP-1, that is responsible for MMP-9 induction.

**Effects of PN-1 silencing in 4T1 tumor cells.** In the following experiments, we examined the consequences of PN-1 down-regulation in 4T1 tumor cells. PN-1 was stably silenced by transfecting 4T1 cells with pSilencer vectors targeting two distinct sites in PN-1 mRNA (shRNA1 and shRNA2); transfection with the empty vector was done as a control. Following selection in puromycin-containing medium, PN-1-KD clones and control clones were isolated and PN-1 protein levels and secreted MMP-9 activity were examined. Clones with efficient shRNA1-mediated (Fig. 3A, black columns, clones 1, 14, 29, and 36) or shRNA2-mediated (Fig. 3A, black columns, clones 1, 8, and 34) PN-1-KD showed a strong decrease in MMP-9 activity (Fig. 3A, white columns). Clones displaying little or no PN-1-KD (Fig. 3A, white columns, shRNA1 clones 3 and 40 and shRNA2 clones 14 and 36) had essentially no change in secreted MMP-9 activity (Fig. 3A, white columns). These results support the link between PN-1 expression and MMP-9 activity that was established in the 16FARN cells. Two representative PN-1-KD clones, clone 1 shRNA1 and clone 1 shRNA2, were analyzed further. Zymography and immunoblot analyses show that both clones synthesized and secreted less MMP-9 than mock-transfected clones or untransfected 4T1 cells (Fig. 3B). Moreover, RT-PCR analysis revealed that, in comparison with control cells, MMP-9 mRNA was essentially undetectable in the PN-1-KD cells, whereas neither PAI-1 nor LRP-1 was altered in these cells (Fig. 3C).

**PN-1 stimulates ERK signaling activity.** Next, we examined the signaling pathways in control and PN-1-KD 4T1 cells. Parental and mock-transfected 4T1 cells have high levels of phospho-STAT3, phospho-p38 mitogen-activated protein kinase, and phospho-Akt, which remained unchanged in the two PN-1-KD clones (Fig. 4A). In contrast, compared with control cells, phospho-ERK1/2 levels were reduced in both PN-1-KD clones, the effect being most pronounced in PN-1-shRNA1 cells (Fig. 4A). To test if there is a link between ERK activity and MMP-9 expression, 4T1 cells were treated with the MEK inhibitor U0126 and MMP-9 protein levels were examined. Even the lowest dose of U0126 caused a >50% decrease in MMP-9 protein levels (Fig. 4B), suggesting that PN-1 signals via the ERK pathway to control MMP-9 expression in 4T1 cells.

Next, 16FARN cells were treated with recombinant PN-1 and ERK1/2 activity was evaluated. Within 15 min, PN-1 triggered an increase in ERK1/2 phosphorylation, which continued to increase and peaked at 30 min (Fig. 4C). This increase was more pronounced when 16FARN cells were incubated with PN-1/IPA complexes (Fig. 4C, bottom). To test if PN-1 stimulates MMP-9 expression via the ERK pathway, 16FARN cells were pretreated with the MEK inhibitor U0126 before PN-1 addition. U0126 pretreatment prevented PN-1 from enhancing MMP-9 levels (Fig. 4D), confirming the importance of ERK activation in the process.

**PN-1 is required for 4T1 metastasis but not for primary tumor growth.** Next, we tested the *in vivo* effect of PN-1 silencing in 4T1 cells. The two PN-1-KD clones (PN-1-shRNA1 clone 1 and PN-1-shRNA2 clone 1) as well as mock-transfected and parental 4T1 cells were injected into mammary fat pads of BALB/c mice and tumor formation was monitored. Over the course of 26 days, there was no significant difference in tumor outgrowth kinetics and tumor size between the PN-1-KD cells and the control 4T1 cells (Fig. 5A). The levels of PN-1 in the KD cells remained low throughout the experiment as revealed by a Western analysis.
carried out on lysates of tumors removed 26 days post-injection (Fig. 5B). To determine whether loss of PN-1 affects the metastatic ability of the 4T1 cells, the lungs of mice sacrificed on day 26 were stained with Bouin’s fixative and the metastatic nodules were quantified. Whereas the tumors induced by parental and mock-transfected 4T1 cells formed multiple large nodules, tumors from the PN-1-KD cells formed very few metastases (Fig. 5C). Quantification revealed a significant 66% and 75% decrease in metastases resulting from PN-1-shRNA1 and shRNA2-KD tumors, respectively. These results show that PN-1, produced by the 4T1 tumor cells, is not essential for primary mammary tumor development. In contrast, the absence of PN-1 dramatically decreases the ability of 4T1 cells to disseminate to the lungs.

Expression of MMP-9 in PN-1-KD 4T1 cells rescues their metastatic potential. To assess if decreased MMP-9 expression in PN-1-KD 4T1 cells was responsible for their low metastatic properties, we generated MMP-9 “rescued” cells. A MMP-9 expression vector or a control empty vector was introduced into PN-1-shRNA1 and PN-1-shRNA2-KD 4T1 cells and stable pools were isolated. MMP-9 expression was restored in each PN-1-KD clone, with the PN-1-shRNA2 cells showing higher levels than the PN-1-shRNA1 cells (Fig. 5D, top). The MMP-9 “rescued” PN-1-KD cells as well as the control PN-1-KD cells were injected in mammary glands of BALB/c mice and tumor size and lung metastases were monitored. Tumor outgrowth of each of the four cell lines was equivalent to the outgrowth of the control (mock) 4T1 cells (Supplementary Fig. S2). Considering the metastatic potential of the cells, the control-rescued PN-1-KD cells formed significantly fewer metastases compared with 4T1 cells (mock; Fig. 5D, bottom), showing that the original PN-1-KD phenotype was maintained. Interestingly, PN-1-shRNA2-MMP-9 tumors gave rise to more metastasis than the 4T1 tumors (mock), whereas PN-1-shRNA1-MMP-9 tumors had the same number as control (Fig. 5D, bottom), perhaps reflecting the higher MMP-9 levels in the former cells (Fig. 5D, top). This experiment shows that ectopic MMP-9 expression in both PN-1-KD clones rescued their metastatic potential. Thus, we conclude that, in the 4T1 mammary tumor model, MMP-9 is responsible for PN-1-mediated metastasis.

In human breast tumors, PN-1 levels correlate with markers of poor prognosis and an increased chance of lung metastasis. There are only a few reports on PN-1 expression in human breast cancer (18), which prompted us to examine PN-1 levels in publicly available gene expression data sets (33). Our analysis shows that PN-1 expression increased in a statistically significant manner with breast tumor grade, and PN-1 levels were significantly higher in ER-α-negative tumors (Fig. 6A). The correlation between ER-α negativity and high PN-1 was validated in additional independent data sets encompassing >350 breast tumors (Supplementary Fig. S3). These results suggest that elevated PN-1 correlates with pathologic parameters predicting poor patient outcome.

To investigate the possibility that elevated PN-1 levels might have prognostic value, a cohort of breast cancer patients with complete clinical information (Gene Expression Omnibus accession nos. GSE2603 and GSE5327; ref. 26, 27) was analyzed. From the combined total of 126 patients, 38 developed metastases, of
which 21 had lung metastases after a 5-year follow-up. Elevated PN-1 expression was significantly associated with lung metastasis probability ($P = 0.039$, log-rank test; Fig. 6B, top) but not with probability of metastasis at other sites ($P = 0.26$; Fig. 6B, bottom).

**Discussion**

Despite recent advances in breast cancer treatment (34, 35), the disease still remains a leading cause of death among women. The identification of novel pathways implicated in breast cancer formation or progression remains a high priority. The work we present here suggests that the serpin PN-1 and its receptor LRP-1 might be interesting targets. Using a combination of in vitro and in vivo experiments with mammary tumor models having distinct metastatic potential, we provide data supporting a role for PN-1 in cancer progression. We show that 4T1 mammary cancer cells require PN-1 to disseminate from the primary tumor to distant organs. Our results suggest a novel mechanism whereby PN-1, complexed with target proteases, binds the LRP-1 receptor and activates ERK signaling, thereby controlling MMP-9 expression and 4T1 metastatic spread (Supplementary Fig. S4). To expand our findings from mammary cancer models to human cancer, we examined publicly available expression data sets, which revealed that significantly higher levels of PN-1 are present in ER-$\alpha$-negative and high-grade breast tumors. Furthermore, an analysis of 126 breast cancer patients revealed that those whose tumors have elevated PN-1 had a significantly higher probability...
of showing lung metastasis on relapse. Results from this combination of approaches suggest that the PN-1/protease/LRP-1 complex might be a novel target for breast cancer therapy.

The LRP-1 receptor binds many proteins and functions as a signaling molecule in addition to its catabolic activity (36). We established the importance of LRP-1 in the PN-1/ERK/MMP-9 pathway that we describe here by various means. We show that PN-1 treatment of control MEFs, but not LRP-1-null MEFs, causes an increase MMP-9 expression. Similarly, LRP-1-KD 168FARN cells failed to produce MMP-9 in response to PN-1. These results rule out the possibility that the transmembrane glycoprotein syndecan-1, which has been shown to bind PN-1 and stimulate ERK activity in LRP-1-null MEFs (37), has a role in MMP-9 induction.

tPA (24) and PAI-1/uPA complexes (38) have also been shown to stimulate ERK activation through LRP-1. We have found that PAI-1/tPA addition to 168FARN cells also increases MMP-9 levels (Supplementary Fig. S5B), suggesting that these closely related serpins stimulate the same pathway, however, with some intriguing differences. Unlike PN-1 that stimulates MMP-9 when added alone to 168FARN cells, PAI-1 requires complexing with a protease (Supplementary Fig. S5A). The use of the P960 peptide, which only prevents PN-1/protease complexes from binding LRP-1, shows that recombinant PN-1 associates with proteases on the 168FARN cells and that these complexes stimulate MMP-9 expression. The reason why PAI-1 cannot complex with endogenous proteases on these cells is not known. Finally, it is interesting to mention that the 4T1 PN-1-KD cells maintain normal PAI-1 expression; however,

![Image](image-url)
down-regulation of the transcription factor Twist, which lies downstream of STAT3 in the 4T1 cells (39), has a similar phenotype as PN-1-KD. Specifically, Twist silencing does not prevent 4T1 mammary tumor outgrowth but decreases metastatic potential (29). PN-1-KD and control 4T1 cells have similar Twist mRNA levels (Supplementary Fig. S6), ruling out a role for Twist in the PN-1/LRP-1/ERK/MMP-9 pathway. MMP-9 has a well-documented role in metastasis in various cancer models (40). Based on our results showing that the re-expression of MMP-9 in the PN-1-KD 4T1 cells restores their metastatic potential, we propose that MMP-9 is the important target that mediates PN-1 effects on metastasis.

Serpins have multiple complex roles in tumor biology. Recently, host-derived PAI-1 was shown to be required for outgrowth of human neuroblastoma cells due to its ability to protect tumor-associated endothelial cells from apoptosis (11). PN-1 is expressed in many cell types including vascular endothelial cells (41) and stromal cells (42). We tested the role of host-derived PN-1 using PN-1-null mice (43) as recipients for 4T1 tumor cells. The outgrowth of primary tumors and appearance of lung metastases were similar in wild-type and PN-1-null mice (Supplementary Fig. S7). Taken together, our results show that host-derived PN-1 does not appear to have a role in 4T1 tumor outgrowth or metastasis, whereas tumor-derived PN-1 is essential for lung metastasis.

Our analysis of publicly available data sets revealed that PN-1 levels are significantly elevated in ER-α-negative tumors. Moreover, PN-1/SERPINE2 was recently reported to be one of the genes predicting poor outcome in breast cancer patients with ER-α-negative tumors (44). Using data from 126 breast cancer patients, we report here that elevated PN-1 expression was significantly associated with lung metastases probability on relapse but not with probability of metastasis at other sites. Taken together, these results support the hypothesis that, in breast cancer, elevated PN-1 levels might serve as a marker of poor prognosis and organ-specific metastatic potential.

Finally, it is worth mentioning that the LRP-1 receptor itself has a documented role in cancer. Indeed, silencing of LRP-1 in a breast cancer tumor model had no effect on primary tumor growth but decreased their metastatic potential (45). Furthermore, invasive properties of some breast and thyroid cancer cells appear to be dependent on LRP-1 (45, 46) and LRP-1 was shown to enhance gelatinase expression and migration of human glioblastoma cells (47). LRP-1 binds multiple serpin/protease complexes, and as we show here, PN-1/protease complexes activate signaling pathways and control expression of proteins with well-documented roles in cancer. Thus, targeting the LRP-1 receptor might be an appropriate therapeutic option.

This serpin cannot replace PN-1 function and promote MMP-9 expression in the 4T1 cells. The reason for this difference remains to be explored.

Our in vivo results with the 4T1 cancer model show that PN-1 is not required for mammary tumor outgrowth but has an essential role in metastasis. Loss of PN-1 causes a decrease of MMP-9 levels, which we show is the essential regulator of the metastatic phenotype. We have also established the importance of ERK signaling in PN-1-mediated MMP-9 expression, by showing that PN-1-KD in 4T1 cells causes a decrease in ERK activity and that pretreatment of 168FARN cells with a MEK inhibitor prevents PN-1 from stimulating MMP-9 expression. Down-regulation of the transcription factor Twist, which lies downstream of STAT3 in the 4T1 cells (39), has a similar phenotype as PN-1-KD. Specifically, Twist silencing does not prevent 4T1 mammary tumor outgrowth but decreases metastatic potential (29). PN-1-KD and control 4T1 cells have similar Twist mRNA levels (Supplementary Fig. S6), ruling out a role for Twist in the PN-1/LRP-1/ERK/MMP-9 pathway. MMP-9 has a well-documented role in metastasis in various cancer models (40). Based on our results showing that the re-expression of MMP-9 in the PN-1-KD 4T1 cells restores their metastatic potential, we propose that MMP-9 is the important target that mediates PN-1 effects on metastasis.

Serpins have multiple complex roles in tumor biology. Recently, host-derived PAI-1 was shown to be required for outgrowth of human neuroblastoma cells due to its ability to protect tumor-associated endothelial cells from apoptosis (11). PN-1 is expressed in many cell types including vascular endothelial cells (41) and stromal cells (42). We tested the role of host-derived PN-1 using PN-1-null mice (43) as recipients for 4T1 tumor cells. The outgrowth of primary tumors and appearance of lung metastases were similar in wild-type and PN-1-null mice (Supplementary Fig. S7). Taken together, our results show that host-derived PN-1 does not appear to have a role in 4T1 tumor outgrowth or metastasis, whereas tumor-derived PN-1 is essential for lung metastasis.

Our analysis of publicly available data sets revealed that PN-1 levels are significantly elevated in ER-α-negative tumors. Moreover, PN-1/SERPINE2 was recently reported to be one of the genes predicting poor outcome in breast cancer patients with ER-α-negative tumors (44). Using data from 126 breast cancer patients, we report here that elevated PN-1 expression was significantly associated with lung metastases probability on relapse but not with probability of metastasis at other sites. Taken together, these results support the hypothesis that, in breast cancer, elevated PN-1 levels might serve as a marker of poor prognosis and organ-specific metastatic potential.

Finally, it is worth mentioning that the LRP-1 receptor itself has a documented role in cancer. Indeed, silencing of LRP-1 in a breast cancer tumor model had no effect on primary tumor growth but decreased their metastatic potential (45). Furthermore, invasive properties of some breast and thyroid cancer cells appear to be dependent on LRP-1 (45, 46) and LRP-1 was shown to enhance gelatinase expression and migration of human glioblastoma cells (47). LRP-1 binds multiple serpin/protease complexes, and as we show here, PN-1/protease complexes activate signaling pathways and control expression of proteins with well-documented roles in cancer. Thus, targeting the LRP-1 receptor might be an appropriate therapeutic option.

Disclosures of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
Received 12/2/08; revised 4/21/09; accepted 5/20/09; published OnlineFirst 7/7/09.

Grant support: Swiss Cancer League KLS-02187-02-2008 (B. Fayard) and Novartis Research Foundation (N.E. Hynes and D. Monard).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Prof. Ruth Mueschel for providing MMP-9-expressing vector and Dr. S. Loeffler for scientific suggestions and discussion of the article.
References

# The Serine Protease Inhibitor Protease Nexin-1 Controls Mammary Cancer Metastasis through LRP-1–Mediated MMP-9 Expression

Bérengère Fayard, Fabrizio Bianchi, Julien Dey, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-08-4573</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2009/06/24/0008-5472.CAN-08-4573.DC1">http://cancerres.aacrjournals.org/content/suppl/2009/06/24/0008-5472.CAN-08-4573.DC1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 47 articles, 16 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/69/14/5690.full.html#ref-list-1">http://cancerres.aacrjournals.org/content/69/14/5690.full.html#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 8 HighWire-hosted articles. Access the articles at: /content/69/14/5690.full.html#related-urls</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>